Clinical Trial Update: Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Everolimus for preventing fibrosis progression in liver transplant patients with recurrent hepatitis C; the study has been t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Recurrent Hepatitis C | Phase 2 | Status: TERMINATED | Results posted: 2012-09-06